Adial Pharmaceuticals, Inc. (AZR) income statement

AZRNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ADIL

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q/A on Oct 21, 2026Score 5/30

Share price

Not available yet

Price, market cap and P/E appear here once daily prices are connected.

Adial Pharmaceuticals, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Research & Development	2.62	3.23	1.27	1.95	8.40	5.85	3.97	0.37	0.18
General & Administrative	5.18	5.06	5.62	8.91	9.34	5.07	4.28	6.62	0.81
Operating Expenses	7.80	8.28	6.89	11	19	11	8.24	6.99	1.00
Total Costs & Expenses	–	–	–	0.55	–	–	–	–	–
Operating Income	-7.80	-8.28	-6.89	-11	-19	-11	-8.24	-6.99	-1.00
Interest & Investment Income	0.15	0.18	0.07	0.06	0.01	0.03	0.10	0.01	0.00
Income from Equity Investments	0.07	-0.55	-0.19	–	–	–	–	–	–
Other Non-Operating Income	-0.18	-4.91	-0.11	0.06	-0.23	0.03	-0.35	-4.64	-0.14
Asset Impairment Charges	–	–	–	–	1.55	–	–	–	–
Gain (Loss) on Investments	–	2.62	2.62	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	-0.01	–	–	–	–
Pretax Income	-7.98	-13	-7.00	-11	-20	-11	-8.59	-12	-1.14
Income Tax Expense	–	–	–	0.00	-0.09	–	–	–	–
Income from Continuing Operations	–	-13	-7.00	-11	–	–	–	–	–
Income from Discontinued Operations	–	–	1.88	-1.94	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	-19	-11	-8.59	–	–
Net Income	-7.98	-13	-5.12	-13	-19	-11	-8.59	-12	-1.14
EPS (Basic)(per share)	-11.93	-68.01	-90.00	-317.75	-650.00	-543.75	-543.75	-1,525.00	-218.75
EPS (Diluted)(per share)	-11.93	-68.01	-90.00	-317.75	-650.00	-543.75	-543.75	-1,525.00	-218.75
Shares Outstanding (Basic, Weighted)(shares)	0.67	0.19	–	0.04	0.03	0.02	0.02	0.01	0.01
Shares Outstanding (Diluted, Weighted)(shares)	0.67	0.19	0.06	0.04	0.03	0.02	0.02	0.01	0.00

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -170.7%

Financial strength

Current ratio: 5.63
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 560.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –